Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual Meeting
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
Notice of Election of Candidate for New Audit & Supervisory Board Members
JCR Revises Full-Year Consolidated Forecast for FY2024
JCR Pharma, The Current Fiscal Year Ordinary Profit Revised Downward to a Loss
Change in Duties of Corporate Officers, Organizational and Personnel Changes
Notice Concerning the Start of Construction of a New Drug Product Plant
JCR Pharmaceuticals Proudly Supports Rare Disease Day 2025
Notice of Partial Correction to “FY2024 Third Quarter Consolidated Financial Results Conference Call Material”
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium 2025 Showcase Research from Its Investigational Treatments for LSDs
Summary of Financial Results for the third quarter 2025
Financial Summary Consolidated Financial Results for the Nine Months ended December 31, 2024 (FY2024) (Japanese standard)
Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2025
FY2024 Third Quarter Consolidated Financial Results Conference Call
JCR Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 84%
JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposiumTM 2025
[Updated]JCR and Modalis Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
JCR Pharmaceuticals Receives MHLW Orphan Drug Designation for JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy